Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most ...
Curanex Pharmaceuticals, Inc. CURX on Thursday said it is expanding its drug development pipeline. Pipeline Expansion Adds New Focus The company's pipeline currently encompasses six core indications, ...
Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...
Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ...
Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple ...
Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...
New research in fruit flies suggests that a decreased desire to eat protein can serve as the earliest known warning sign of ...
A new approach using lipid nanoparticles to deliver genetic material is showing promise in tackling two major challenges in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results